Verve Therapeutics Inc (VERV)

08:16 AM

Lilly completes tender offer for Verve Therapeutics shares - Investing.com

08:16 AM

08:03 AM

Lilly and Verve announce expiration of Verve tender offer | Eli Lilly and Company - Eli Lilly

08:03 AM

08:00 AM

Lilly Secures 55.7% of Verve Shares in $10.50 Cash Plus CVR Deal, Closing Set for July 25 - Stock Titan

08:00 AM

Jul 23, 2025

Verve Therapeutics Inc. Stock Analysis and ForecastRapid portfolio appreciation - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition - MSN

Jul 23, 2025

Jul 22, 2025

What drives Verve Therapeutics Inc. stock priceBreakthrough wealth creation - Autocar Professional

Jul 22, 2025

Jul 22, 2025

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B - MSN

Jul 22, 2025

Jul 22, 2025

Eli Lilly, Verve Therapeutics receive early termination from US FTC - MLex

Jul 22, 2025

Jul 22, 2025

What analysts say about Verve Therapeutics Inc. stockHigh-yield investments - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is Verve Therapeutics Inc. a good long term investmentPhenomenal trading returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

(VERV) Trading Advice - news.stocktradersdaily.com

Jul 22, 2025

Jul 21, 2025

3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

Jul 21, 2025

Jul 19, 2025

Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com

Jul 19, 2025

Jul 19, 2025

Is Verve Therapeutics Inc. stock a good hedge against inflationFree AI-Driven Trading Strategies - beatles.ru

Jul 19, 2025

Jul 16, 2025

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing - The Pharma Letter

Jul 16, 2025

Jul 15, 2025

Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360

Jul 15, 2025

Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada

Jul 15, 2025

Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa

Jul 15, 2025

Jul 15, 2025

Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks

Jul 15, 2025

Jul 14, 2025

Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 14, 2025

Jul 13, 2025

Verve Therapeutics, Inc. (VERV): A Bull Case Theory - MSN

Jul 13, 2025

Jul 07, 2025

Prime Medicine soars as Jones sees it as an acquisition target - Seeking Alpha

Jul 07, 2025

Jul 06, 2025

Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN

Jul 06, 2025

Jun 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Jun 27, 2025

Jun 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar

Jun 27, 2025

Jun 24, 2025

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN

Jun 24, 2025

Jun 23, 2025

Lilly To Acquire Verve For One-Time Cardiovascular Treatments - Insider Monkey

Jun 23, 2025

Jun 20, 2025

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week - AOL.com

Jun 20, 2025

Jun 19, 2025

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? - Yahoo Finance

Jun 19, 2025

Jun 18, 2025

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire

Jun 18, 2025

Jun 18, 2025

Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga

Jun 18, 2025

Jun 18, 2025

Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize

Jun 18, 2025

Jun 18, 2025

Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus

Jun 18, 2025

Jun 18, 2025

Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN

Jun 18, 2025

Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025

Jun 18, 2025

Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com

Jun 18, 2025

Jun 18, 2025

Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks

Jun 18, 2025

Jun 18, 2025

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN

Jun 18, 2025